Product Details

Modest Gains in SMO Usage

Overall sponsor use of SMOs for clinical projects has risen by several percentage points. Larger average numbers of SMO sites are being used per clinical project.

Usage growth has come despite mediocre SMO performance levels. Across a variety of factors, SMO performance ratings are typically on par with or lower than those of individual investigative sites and site networks, according to a new CenterWatch survey.

Japanese Sponsors Drive Clinical Trials Growth

The Japanese clinical trials industry is poised to play a growing role in global development projects. With mutual recognition of ICH-GCP guidelines, Japanese, U.S. and European sponsors can submit study data from their home country to regulatory authorities within the tripartite.

Given weak domestic infrastructure, harmonization is stimulating the placement of Japanese-sponsored clinical trials among U.S. investigative sites. CROs in Japan face high demand, in part to help build study conduct infrastructure.

Also in this issue:

• CentreStage Europe: Training Resources
• Eye On: Multiple Sclerosis